Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein
Keywords: Human cytomegalovirus; IE2; Drug repurposing; Manidipine dihydrochloride; IE-2; Immediate-Early 2; MND; manidipine dihydrochloride; NTZ; nitazoxanide;